• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.16% Nasdaq Down0.08%

    Inovio Pharmaceuticals, Inc. (INO)

    -NasdaqGS
    7.92 Down 0.22(2.70%) Jul 2, 4:00PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Inovio Pharmaceuticals, Inc.
    660 West Germantown Pike
    Suite 100
    Plymouth Meeting, PA 19462
    United States - Map
    Phone: 267-440-4200
    Fax: 267-440-4242
    Website: http://www.inovio.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:106

    Business Summary 

    Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. The company’s SynCon immunotherapy design has the ability to break the immune system’s tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, influenza, and Ebola. Inovio Pharmaceuticals, Inc. has collaborative development agreement with GeneOne Life Sciences to co-develop an Ebola vaccine through phase I clinical trials. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Inovio Pharmaceuticals, Inc.

    Corporate Governance 
    Inovio Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Jun 1, 2015 is 7. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 3; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. J. Joseph Kim Ph.D., 46
    Chief Exec. Officer, Pres, Director and Member of Fin. Committee
    975.00K0.00
    Mr. Peter D. Kies , 52
    Chief Financial Officer
    481.00K0.00
    Dr. Niranjan Y. Sardesai Ph.D., 47
    Chief Operating Officer
    498.00K0.00
    Dr. Mark L. Bagarazzi M.D., 54
    Chief Medical Officer
    501.00K0.00
    Mr. Bernie Hertel ,
    VP of Investor Relations and Communications
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders